Who are Risperidone and Ramelteon's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/risperidone-and-ramelteon.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Risperidone and Ramelteon — Competitive Intelligence Brief

Risperidone and Ramelteon (Risperidone and Ramelteon) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic + melatonin receptor agonist combination. Area: Psychiatry / Sleep Medicine.

marketed Atypical antipsychotic + melatonin receptor agonist combination Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors Psychiatry / Sleep Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Risperidone and Ramelteon (Risperidone and Ramelteon) — All India Institute of Medical Sciences, Bhubaneswar. This combination uses risperidone (a dopamine antagonist) to manage psychotic symptoms and ramelteon (a melatonin receptor agonist) to improve sleep disturbances.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Risperidone and Ramelteon TARGET	Risperidone and Ramelteon	All India Institute of Medical Sciences, Bhubaneswar	marketed	Atypical antipsychotic + melatonin receptor agonist combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic + melatonin receptor agonist combination class)

All India Institute of Medical Sciences, Bhubaneswar · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Risperidone and Ramelteon — Competitive Intelligence Brief. https://druglandscape.com/ci/risperidone-and-ramelteon. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab